CO2021012310A2 - Composiciones y métodos para tratar laminopatías - Google Patents

Composiciones y métodos para tratar laminopatías

Info

Publication number
CO2021012310A2
CO2021012310A2 CONC2021/0012310A CO2021012310A CO2021012310A2 CO 2021012310 A2 CO2021012310 A2 CO 2021012310A2 CO 2021012310 A CO2021012310 A CO 2021012310A CO 2021012310 A2 CO2021012310 A2 CO 2021012310A2
Authority
CO
Colombia
Prior art keywords
laminopathies
treating
methods
compositions
lamina
Prior art date
Application number
CONC2021/0012310A
Other languages
English (en)
Inventor
Sirika Wood
Kartik Ramamoorthi
Stephanie Tagliatela
Anne Tanenhaus
Original Assignee
Encoded Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Encoded Therapeutics Inc filed Critical Encoded Therapeutics Inc
Publication of CO2021012310A2 publication Critical patent/CO2021012310A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0276—Knock-out vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A01K2217/077—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out heterozygous knock out animals displaying phenotype
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0375—Animal model for cardiovascular diseases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Environmental Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)

Abstract

La presente descripción proporciona composiciones y métodos para tratar, prevenir, o inhibir laminopatías. En un aspecto, la descripción proporciona constructos de ácido nucleico y/o vectores que comprenden una secuencia de nucleótidos que codifica lámina A y/o lámina C.
CONC2021/0012310A 2019-02-28 2021-09-21 Composiciones y métodos para tratar laminopatías CO2021012310A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962812021P 2019-02-28 2019-02-28
PCT/US2020/020520 WO2020176896A1 (en) 2019-02-28 2020-02-28 Compositions and methods for treating laminopathies

Publications (1)

Publication Number Publication Date
CO2021012310A2 true CO2021012310A2 (es) 2021-09-30

Family

ID=72238989

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2021/0012310A CO2021012310A2 (es) 2019-02-28 2021-09-21 Composiciones y métodos para tratar laminopatías

Country Status (17)

Country Link
US (1) US20220193264A1 (es)
EP (1) EP3931336A4 (es)
JP (1) JP2022522196A (es)
KR (1) KR20210144696A (es)
CN (1) CN113840927A (es)
AU (1) AU2020229382A1 (es)
BR (1) BR112021016783A2 (es)
CA (1) CA3131776A1 (es)
CL (1) CL2021002262A1 (es)
CO (1) CO2021012310A2 (es)
EA (1) EA202192376A1 (es)
IL (1) IL285886A (es)
MA (1) MA55087A (es)
MX (1) MX2021010301A (es)
SG (1) SG11202109362XA (es)
TW (1) TW202045725A (es)
WO (1) WO2020176896A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA49153A (fr) * 2017-05-19 2021-03-24 Encoded Therapeutics Inc Éléments régulateurs à haute activité
AU2021409806A1 (en) * 2020-12-23 2023-06-15 University Of Florida Research Foundation, Incorporated Increased packaging efficiency of vector for cardiac gene therapy
GB202100311D0 (en) * 2021-01-11 2021-02-24 Univ Court Of The Univ Of Aberdeen Treatment for Lipodystrophy
US20220362319A1 (en) * 2021-05-12 2022-11-17 PPM Labs LLC Cannabinoid Concentration Process
EP4198053A1 (en) * 2021-12-15 2023-06-21 Universitätsklinikum Hamburg-Eppendorf Lmna gene expression for treatment of laminopathies

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7838531B2 (en) * 2002-10-18 2010-11-23 The United States Of America As Represented By The Department Of Health And Human Services Farnesyltransferase inhibitors for treatment of laminopathies, cellular aging and atherosclerosis
WO2007047913A2 (en) * 2005-10-20 2007-04-26 Isis Pharmaceuticals, Inc Compositions and methods for modulation of lmna expression

Also Published As

Publication number Publication date
EA202192376A1 (ru) 2021-12-27
EP3931336A4 (en) 2023-01-04
WO2020176896A1 (en) 2020-09-03
US20220193264A1 (en) 2022-06-23
SG11202109362XA (en) 2021-09-29
CL2021002262A1 (es) 2022-05-27
BR112021016783A2 (pt) 2021-11-09
CN113840927A (zh) 2021-12-24
CA3131776A1 (en) 2020-09-03
MX2021010301A (es) 2021-11-12
EP3931336A1 (en) 2022-01-05
IL285886A (en) 2021-10-31
JP2022522196A (ja) 2022-04-14
AU2020229382A1 (en) 2021-09-16
MA55087A (fr) 2022-01-05
TW202045725A (zh) 2020-12-16
KR20210144696A (ko) 2021-11-30

Similar Documents

Publication Publication Date Title
CO2021012310A2 (es) Composiciones y métodos para tratar laminopatías
BR112018076190A2 (pt) ortólogos e sistemas crispr tipo vi
BR112019000195A2 (pt) composições e métodos relacionados a sistemas celulares terapêuticos que expressam rna exógeno
SA517390590B1 (ar) Ix عامل معدل، وتركيبات وطرق واستخدامات لنقل الجين إلى الخلايا، والأعضاء والأنسجة
BR112018069417A2 (pt) método para fornecer rna fita simples e ssrna
BR112017020054A2 (pt) anticorpos para icos
BR112018013930A2 (pt) vírus oncolítico, vírus que expressa três genes heterólogos, composição farmacêutica, vírus para o uso, produto de fabricação, método de tratamento de câncer e uso do vírus
UY37803A (es) Métodos y composiciones para tratar un evento de sangrado en un sujeto que padece hemofilia
BR112018013065A2 (pt) composições e métodos para o tratamento de hemoglobinopatias
MX2018005829A (es) Composiciones para tratar el cabello.
NZ742787A (en) Compositions comprising bacterial strains
BR112018004620A2 (pt) moduladores da expressão de kras
BR112017023821A2 (pt) moduladores de k-ras
BR112017023692A2 (pt) moléculas imunoterapêuticas glican-dependentes
NZ733882A (en) Compositions for modulating c9orf72 expression
UY36357A (es) Composiciones y métodos para la inhibición de la expresión génica de hao1 (hidroxiácido oxidasa 1 (glicolato oxidasa))
MX2018016057A (es) Composiciones y metodos para tratar enfermedades cardiovasculares.
MX2021008487A (es) Escisión y poliadenilación del arn nuclear dirigido con crispr-cas.
WO2016065349A3 (en) Short non-coding protein regulatory rnas (sprrnas) and methods of use
WO2015148580A3 (en) Una oligomers having reduced off-target effects in gene silencing
EA201891628A1 (ru) Ингибирование аллергической реакции с использованием ингибитора il-33
AR119677A1 (es) Dominios de unión anti-cd38
MX2020006297A (es) Variantes de cd19.
BR112021022951A2 (pt) Composições e métodos para o tratamento de doenças mediadas por atpase
BR112018006986A2 (pt) métodos e composições para contrações musculares indesejadas ou anormais